Metallothionein-II improves motor function recovery and increases spared tissue after spinal cord injury in rats
Por:
Arellano-Ruiz S., Rios C., Salgado-Ceballos H., Méndez-Armenta M., Del Valle-Mondragón L., Nava-Ruiz C., Altagracia-Martínez M., Díaz-Ruiz A.
Publicada:
11 abr 2012
Categoría:
Neuroscience (miscellaneous)
Resumen:
After spinal cord injury (SCI), a complex cascade of pathophysiological processes rapidly damages the nervous tissue. The initial damage spreads to the surrounding tissue by different mechanisms, including oxidative stress. We have recently reported that the induction of metallothionein (MT) protein is an endogenous rapid-response mechanism after SCI. Since the participation of MT in neuroprotective processes after SCI is still unknown, the aim of the present study was to evaluate the possible neuroprotective effect of exogenously administered MT-II during the acute phase after SCI in rats. Female Wistar rats weighing 200-250g were submitted to spinal cord contusion by means of a computer-controlled device (NYU impactor). Rats received several doses of MT-II (3.2, 10 and 100 mu g) at 2 and 8h after SCI. Results of the BBB scale were statistically analysed using an ANOVA of repeated-measures, followed by Tukey's test. Among the three doses tested, only 10 and 100 mu g were able to signi
Filiaciones:
Arellano-Ruiz S.:
Departamento de Neuroquímica, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suarez S.S.A., Mexico
Maestría en Ciencias Farmacéuticas, Universidad Autónoma Metropolitana, Unidad Xochimilco, Mexico
Rios C.:
Departamento de Neuroquímica, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suarez S.S.A., Mexico
Salgado-Ceballos H.:
Centro de Investigación del proyecto CAMINA A.C., Mexico
Unidad de Investigación Médica en Enfermedades Neurológicas, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Mexico
Méndez-Armenta M.:
Laboratorio de Neuropatología, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suarez S.S.A., Mexico
Del Valle-Mondragón L.:
Departamento de Farmacología, Instituto Nacional de Cardiología Ignacio Chávez S.S.A., Mexico
Nava-Ruiz C.:
Laboratorio de Neuropatología, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suarez S.S.A., Mexico
Altagracia-Martínez M.:
Maestría en Ciencias Farmacéuticas, Universidad Autónoma Metropolitana, Unidad Xochimilco, Mexico
Díaz-Ruiz A.:
Departamento de Neuroquímica, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suarez S.S.A., Mexico
|